QIAGEN NV to acquire Cellesis Limited
QIAGEN NV has reached an agreement to acquire Cellestis Limited for approximately AU$341 million in cash, providing QIAGEN with access to a novel ‘pre-molecular’ technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.
The acquisition of Cellestis will provide QIAGEN with exclusive rights to QuantiFERON technology, a proprietary approach for disease detection and monitoring.
QuantiFERON is complementary to QIAGEN’s portfolio of molecular diagnostics. Its high sensitivity and ability to provide clinically relevant information means that this technology can be used ahead of DNA- or RNA-based molecular testing. Greater use of QuantiFERON technology can help guide and drive the use of traditional DNA- and RNA-based molecular diagnostics.
Director of scientific R&D firm fined $195K+ over biogas experiments
The fine follows a 2022 incident in which a doctor sustained serious injuries after exposure to...
7th edition of STEM Equity Monitor now available
The latest national data resource on diversity in STEM has new design features intended to...
Professor Girish Dwivedi wins 2026 WA Pearcey Entrepreneur of the Year Award
As part of the 35th annual WAITTA INCITE Awards, Dwivedi was recognised for his contribution to...
